基于组织的长非编码 RNA“PVT1、TUG1 和 MEG3”特征可预测卵巢癌对顺铂的耐药性。
Tissue-based long non-coding RNAs "PVT1, TUG1 and MEG3" signature predicts Cisplatin resistance in ovarian Cancer.
机构信息
Clinical Pathology/Hematology & Biomedical Research Departments, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Biomedical Research Department, Global Research Labs, Cairo, Egypt.
Department of Obstetrics and Gynecology Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
出版信息
Genomics. 2020 Nov;112(6):4640-4646. doi: 10.1016/j.ygeno.2020.08.005. Epub 2020 Aug 8.
OBJECTIVES
The current study aimed to investigate the potentiality of three lncRNAs "Plasmacytoma variant translocation 1(lnc-PVT1), Taurine upregulated gene type 1(lnc-TUG1) and Maternally expressed gene 3 (lnc-MEG-3)", to predict Cisplatin resistance in ovarian cancer (OC), in addition, to access their prognostic significance.
METHODS
The expression level of lncRNAs were measured in 100 formalin-fixed paraffin-embedded tissue (FFET) samples of OC patients who were treated by Cisplatin-based chemotherapy using qPCR.
RESULTS
The results showed that lnc_PVT1 was significantly upregulated by 2.3 folds in Cisplatin resistant tissues, while, lnc-TUG1 and lnc-MEG3 were downregulated by 1.2 and 3 folds, respectively. In addition, the three lncRNAs exhibited high sensitivity and specificity in predicting chemo-resistance and they were negatively associated with OS and progression-free survival (p < 0.001).
CONCLUSION
The lnc-PVT1, lnc-TUG1, and lnc-MEG3 transcriptome signatures could be used for predicting resistance to Cisplatin in OC patients.
目的
本研究旨在探讨三种长链非编码 RNA（lnc-PVT1、lnc-TUG1 和 lnc-MEG3）在预测卵巢癌（OC）顺铂耐药中的潜力，并评估其预后意义。
方法
采用 qPCR 检测 100 例接受顺铂为基础的化疗的 OC 患者福尔马林固定石蜡包埋组织（FFET）样本中 lncRNAs 的表达水平。
结果
结果显示，lnc-PVT1 在顺铂耐药组织中显著上调 2.3 倍，而 lnc-TUG1 和 lnc-MEG3 分别下调 1.2 倍和 3 倍。此外，这三种 lncRNAs 在预测化疗耐药方面具有较高的敏感性和特异性，且与 OS 和无进展生存期（p<0.001）呈负相关。
结论
lnc-PVT1、lnc-TUG1 和 lnc-MEG3 的转录组特征可用于预测 OC 患者对顺铂的耐药性。
Zotero 插件